There was encouraging news from the laboratory for ValiRx and its lead compound, VAL201 for cancer.
Only registred members can create thier own customized alerts.
ValiRx focus on the treatment of cancer, specialising in epigenomic and genetic analysis. Our technologies and products however can also be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and is focused on creating a portfolio of innovative products through investment in specific development projects. We actively manage projects within this portfolio as a trading company and are not an investment vehicle.